<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186316</url>
  </required_header>
  <id_info>
    <org_study_id>BMT155</org_study_id>
    <secondary_id>79000</secondary_id>
    <secondary_id>BMT155</secondary_id>
    <nct_id>NCT00186316</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells</brief_title>
  <official_title>A Phase I/II Study of Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell
      transplant will receive 6 vaccinations of donor derived dendritic cells combined with
      specific protein produced by multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate feasibility and safety of vaccination with allogeneic idiotype-pulsed dendritic
      cells following mixed chimeric allogeneic transplantation for multiple myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient will complete 4 vaccinations of monthly interval</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immune response. Immune response analysis will be done on all patients who are enrolled in the study. Patients who completed a minimum of 4 vaccinations will be included in immune response.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Idiotype-pulsed allogeneic dendritic cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1. For specimen collection and idiotype protein development:

          -  Must be secretory myeloma with at least .5g/dl serum IgG protein

          -  Clinically stage 2 or 3 multiple myeloma

          -  Karnofsky performance status of 70 or greater

             2. For Vaccination:

          -  Eligible patients must have completed tandem autologous and nonmyeloablative
             allogeneic transplant for multiple myeloma at Stanford University Medical Center with
             stable disease or complete response to prevaccine therapy

          -  Karnofsky performance status of 70 or greater.

          -  ALT and AST must be &lt;2X upper limit of normal. Total bilirubin &lt; 1.5X upper limit of
             normal.

          -  Serum creatinine &lt;1.5X upper limit of normal.

          -  Hemoglobin &gt;9g/dl

          -  Patients must be HIV negative.

          -  Patients must provide signed, informed consent

        Donor Inclusion Criteria (allo donor is the same donor used for non-myeloablative
        transplant)

          -  Age &gt;17 years

          -  HIV negative

          -  Must provide signed, informed consent

        Exclusion Criteria:1. For specimen collection and idiotype protein development:

          -  Patients with non-secretory myeloma

          -  Severe psychological or medical illness

          -  Pregnant or lactating women

          -  Subjects with &gt; Grade I toxicity by NCI-CTC v 3.0

          -  Subjects with prognosis &lt; 6 months

             2. For Vaccination:

          -  &lt; 75 mg of idiotype protein purified from the patients serum

          -  &lt; 25 million allogeneic idiotype-pulsed dendritic cells produced for vaccination

          -  Evidence of grade II-IV acute GVHD (defined in section 5E)

          -  Patients with evidence of myeloma disease progression as (defined below)

          -  Severe psychological or medical illness or concomitant medications which may interfere
             with the study as determined by the clinical investigator

          -  Patients on any other investigational agents

          -  Pregnant or lactating women

          -  Patients on any therapy for multiple myeloma or any chemotherapy drug, or
             immunomodulatory agent for treatment of multiple myeloma (e.g. thalidomide)

          -  Any patient on more than two of the following immunosuppressive agents or at a dose
             greater than that indicated for a single immunosuppressive agent:

               1. Mycophenolate Mofetil (MMF)- no greater than 1000mg twice a day

               2. Prednisone- no greater than .5mg/kg/day

               3. Cyclosporine- no greater than 300mg/day

               4. Tacrolimus (FK506)- no greater than 4mg/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Levy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>August 21, 2009</last_update_submitted>
  <last_update_submitted_qc>August 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ronald Levy, Principal Investigator</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

